ARQT
Income statement / Annual
Last year (2025), Arcutis Biotherapeutics Inc's total revenue was $376.07 M,
an increase of 91.34% from the previous year.
In 2025, Arcutis Biotherapeutics Inc's net income was -$16.14 M.
See Arcutis Biotherapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$376.07 M |
$196.54 M |
$59.61 M |
$3.69 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$36.70 M
|
$19.13 M
|
$4.99 M
|
$754.00 K
|
$763.00 K
|
$455.00 K
|
$195.00 K
|
$0.00
|
$0.00
|
| Gross Profit |
$339.38 M
|
$177.41 M
|
$54.62 M
|
$2.93 M
|
-$763.00 K
|
-$455.00 K
|
-$195.00 K
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.9
|
0.9
|
0.92
|
0.8
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$77.05 M
|
$76.42 M
|
$110.58 M
|
$182.44 M
|
$145.56 M
|
$115.31 M
|
$36.52 M
|
$17.94 M
|
$3.41 M
|
| General & Administrative Expenses |
$0.00
|
$222.49 M
|
$0.00
|
$122.12 M
|
$60.97 M
|
$0.00
|
$0.00
|
$1.80 M
|
$695.00 K
|
| Selling & Marketing Expenses |
$0.00
|
$6.90 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$274.55 M
|
$229.39 M
|
$185.15 M
|
$122.12 M
|
$60.97 M
|
$20.88 M
|
$6.42 M
|
$1.80 M
|
$695.00 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$173.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$351.60 M
|
$305.81 M
|
$295.72 M
|
$304.56 M
|
$205.77 M
|
$136.19 M
|
$42.94 M
|
$19.74 M
|
$4.11 M
|
| Cost And Expenses |
$388.30 M
|
$324.94 M
|
$300.71 M
|
$305.31 M
|
$206.53 M
|
$136.65 M
|
$43.13 M
|
$19.74 M
|
$4.11 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$173.00 K
|
$967.00 K
|
$1.14 M
|
$0.00
|
$0.00
|
| Interest Expense |
$12.08 M
|
$27.17 M
|
$29.71 M
|
$15.65 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$5.37 M
|
$2.60 M
|
$1.88 M
|
$1.25 M
|
$763.00 K
|
$455.00 K
|
$195.00 K
|
$19.74 M
|
$4.11 M
|
| EBITDA |
$2.48 M |
-$109.63 M |
-$227.43 M |
-$294.55 M |
-$205.59 M |
-$135.22 M |
-$41.80 M |
$480.00 K |
-$872.00 K |
| EBITDA Ratio |
0.01
|
-0.56
|
-3.82
|
-79.91
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.03
|
-0.65
|
-4.04
|
-81.83
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$2.74 M
|
-$11.00 M
|
-$17.93 M
|
-$9.83 M
|
$173.00 K
|
$967.00 K
|
$1.14 M
|
$480.00 K
|
-$872.00 K
|
| Income Before Tax |
-$14.97 M
|
-$139.39 M
|
-$259.03 M
|
-$311.46 M
|
-$206.36 M
|
-$135.68 M
|
-$42.00 M
|
-$19.26 M
|
-$4.98 M
|
| Income Before Tax Ratio |
-0.04
|
-0.71
|
-4.35
|
-84.5
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$1.17 M
|
$647.00 K
|
$3.11 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$16.14 M
|
-$140.04 M
|
-$262.14 M
|
-$311.46 M
|
-$206.36 M
|
-$135.68 M
|
-$42.00 M
|
-$19.26 M
|
-$4.98 M
|
| Net Income Ratio |
-0.04
|
-0.71
|
-4.4
|
-84.5
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.13 |
-1.16 |
-3.78 |
-5.66 |
-4.17 |
-3.8 |
-1.1 |
-0.53 |
-4.71 |
| EPS Diluted |
-0.13 |
-1.16 |
-3.78 |
-5.66 |
-4.17 |
-3.8 |
-1.1 |
-0.53 |
-4.71 |
| Weighted Average Shares Out |
$127.23 M
|
$120.96 M
|
$69.31 M
|
$55.03 M
|
$49.41 M
|
$35.67 M
|
$38.09 M
|
$36.24 M
|
$1.06 M
|
| Weighted Average Shares Out Diluted |
$127.23 M
|
$120.96 M
|
$69.31 M
|
$55.03 M
|
$49.41 M
|
$35.67 M
|
$38.09 M
|
$36.24 M
|
$1.06 M
|
| Link |
|
|
|
|
|
|
|
|
|
